G protein-coupled receptor 156Genealiases: DFNB121 · GABABL · PGR28
Q-omics provides the consensus-scored GPR156 profile across patient tissues and cancer cell-line models. GPR156 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GPR156 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, GPR156 RNA expression shows 17,151 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, HNSC, and TGCT as cancer lineages where GPR156 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR156 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR156 survival associations across molecular data types. GPR156 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR156 RNA expression–survival associations across cancer types. High GPR156 expression shows unfavorable associations in KIRP, UCEC, LGG and MESO, but favorable associations in UVM and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GPR156 RNA expression.
This table summarizes GPR156 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR156. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR156 shows lower tumor expression in COAD and BLCA and higher tumor expression in HNSC, THCA, LIHC and LUSC. The HNSC box plot shows higher GPR156 RNA expression in tumor versus normal tissue (log2 FC = +0.711, t-test p < 0.001).
This table shows molecular features associated with GPR156 in patient tissues and cancer cell lines. In patient samples, GPR156 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR156 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
